ADMA Biologics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $124,395 | $114,493 | $139,163 | $134,224 |
Gross Profit | 86,277 | 80,750 | 88,816 | 75,626 |
EBITDA | 57,281 | 61,066 | 65,267 | 51,213 |
EBIT | 53,661 | 59,227 | 63,221 | 49,190 |
Net Income | 37,822 | 45,328 | 49,379 | 36,428 |
Net Change In Cash | 124,395 | 114,493 | 139,163 | 134,224 |
Free Cash Flow | 27,283 | 55,706 | 34,555 | -1,075 |
Cash | 136,020 | 138,153 | 87,630 | 61,385 |
Basic Shares | 230,337 | 239,955 | 243,854 | 244,664 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $510,173 | $426,454 | $258,215 | $154,080 |
Gross Profit | 292,765 | 219,553 | 88,942 | 35,265 |
EBITDA | 197,862 | 147,689 | 5,120 | -39,512 |
EBIT | 189,766 | 139,644 | -3,212 | -46,625 |
Net Income | 146,930 | 197,673 | -28,239 | -65,904 |
Net Change In Cash | 510,173 | 426,454 | 258,215 | 154,080 |
Cost of Revenue | 35,432 | |||
Free Cash Flow | 27,821 | 110,097 | 3,819 | -73,419 |
Cash | 87,630 | 103,147 | 51,352 | 86,522 |
Basic Shares | 244,904 | 243,342 | 223,977 | 197,874 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | $0.16 |
2026-03-31 | $0.17 |
2025-12-31 | $0.21 |
2025-09-30 | $0.16 |